Ardelyx, Inc.

  • Moat Score
  • Safety Score
  • Market Cap $1.19B
  • PE -30
  • Debt $150.85M
  • Cash $64.93M
  • EV $1.28B
  • FCF -$45.82M

Earnings

loading chart...

Sales & Net Margins

loading chart...
Earnings-$39.14M
EBIT-$27.95M
ROE-23%
ROA-6%
FCF-$45.82M
Equity$173.29M
Growth Stability1
PE-30.41
PB6.87
P/FCF-25.98
P/S3.57
Price/Cash0.05
Debt/Equity0.87
Debt/FCF-3.29
Net Margins-12%
Gross Margins85%
Op. Margins-8%
Sales Growth YoY238%
Sales Growth QoQ18%
Sales CAGR53%
Equity CAGR-1%
Earnings Growth YoY-116%
Earnings Growth QoQ-674%
Sales CAGR 5Y158%
Equity CAGR 5Y6%
Earnings CAGR 3Y391%
Sales CAGR 3Y391%
Equity CAGR 3Y52%
Market Cap$1.19B
Revenue$333.62M
Assets$435.75M
Total Debt$150.85M
Cash$64.93M
Shares Outstanding235.23M
EV1.28B
Moat Score5%
Safety Score65%
Working Capital278.62M
Current Ratio4.58
Gross Profit$283.06M
Shares Growth 3y26%
Equity Growth QoQ9%
Equity Growth YoY4%

Assets & ROA

loading chart...

Stockholders Equity & ROE

loading chart...
Ardelyx Inc is a biotechnology company focused on the discovery, development, and commercialization of molecule and polymeric therapeutics to treat the gastrointestinal tract and cardiorenal diseases. The company has a proprietary drug discovery and design platform. Its lead product candidate is tenapanor, which aims to reduce the absorption of dietary sodium and phosphorus for the treatment of kidney disease, irritable bowel syndrome with constipation, and hyperphosphatemia in patients with dialysis.

SEC Filings

Direct access to Ardelyx, Inc. (ARDX) Annual Reports (10K) and Quarterly Reports (10Q) from the SEC website.

  • 2024
    • 10-K Dec 31
    • 10-Q Sep 30
    • 10-Q Jun 30
    • 10-Q Mar 31
  • 2023
    • 10-K Dec 31
    • 10-Q Sep 30
    • 10-Q Jun 30
    • 10-Q Mar 31
  • 2022
    • 10-K Dec 31
    • 10-Q Sep 30
    • 10-Q Jun 30
    • 10-Q Mar 31

Sector Comparison

How does Ardelyx, Inc. compare to its competitors?

Loading chart...

Peter Lynch's Chart

This chart shows the current pricing of Ardelyx, Inc. compared to its past. The addition of the earnings trend line provides further insights into the company's earnings power.

loading chart...

Ardelyx, Inc. Discounted Cash Flow

Fully customizable DCF calculator online for Ardelyx, Inc..

= -$458M
012345678910TV
fcf-$46M-$46M-$46M-$46M-$46M-$46M-$46M-$46M-$46M-$46M-$46M-$458M
DCF-$42M-$38M-$34M-$31M-$28M-$26M-$24M-$21M-$19M-$18M-$177M
Value-$458M

Competitiveness and MOAT

High margins render the company resilient under dire circumstances, hence able to drive competitors out or acquire them. ROE and ROA measure the average flow generated by each invested dollar. Their marginal value is a forecast of future growth, and it is considered by Buffett and Munger the most important single indicator.

Years12/201512/201612/201712/201812/201912/202012/202112/202212/202312/2024TTM
Net Margins-123%--153%-4K%-2K%-1K%-2K%-129%-53%-12%-12%
ROA--53%-40%-50%-35%-45%-103%-34%-21%-6%-6%
ROE--58%-46%-79%-51%-75%-191%-68%-40%-23%-23%

Safety and Stability

Being debt the number one cause of investment losses and company death, the ratio Debt/FCF is of utmost importance to guarantee safety. On the other hand the Graham’s stability measures the drawdown of earnings, hence indicating the reliability of the flow generated by the company.

Years12/201512/201612/201712/201812/201912/202012/202112/202212/202312/2024TTM
Debt over FCF----0.74-0.68-0.64-0.42-0.41-0.58-3.29-3.29
Debt over Equity---0.450.280.420.790.290.310.870.87
Growth Stability----------1

Growth

Growth can be dangerous when forecasting, simply projecting the current growth is in general wrong. A company passes through multiple phases, from being young and unprofitable, to the first periods of profitability and high growth, until it arrives at a period of regime with limited growth. Identifying in which phase the company is in may help forecasting.

Years12/201512/201612/201712/201812/201912/202012/202112/202212/202312/2024CAGR 5Y
Revenue YoY growth----94%103%43%33%417%139%168%158%
Earnings YoY growth-279%-43%42%4%-1%68%-58%-2%-41%-
Equity YoY growth-77%-28%-17%61%-32%-34%19%70%4%6%
FCF YoY growth-29%-31%5%9%6%89%-55%28%-49%-